MediWound (MDWD) Expected to Announce Quarterly Earnings on Thursday

MediWound (NASDAQ:MDWD) is anticipated to release its Q3 2026 results before the market opens on Thursday, November 12th. Analysts expect MediWound to post earnings of ($0.7067) per share and revenue of $6.73 million for the quarter. Individuals may visit the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, November 12, 2026 at 8:30 AM ET.

MediWound (NASDAQ:MDWD) last released its earnings results on Thursday, August 13th. The biopharmaceutical company reported ($0.77) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.01). MediWound had a negative return on equity of 47.24% and a negative net margin of 170.10%. The business had revenue of $3.09 million for the quarter, compared to analyst estimates of $2.59 million. On average, analysts expect MediWound to post ($2.37) EPS for the current fiscal year and ($2.30) EPS for the next fiscal year.

MediWound Trading Down 1.2%

Shares of MediWound stock opened at $14.08 on Tuesday. MediWound has a 52-week low of $11.80 and a 52-week high of $19.70. The company has a 50 day moving average of $13.16 and a 200 day moving average of $15.14.

Analyst Ratings Changes

Several equities research analysts recently commented on the stock. Alliance Global Partners reiterated a “buy” rating on shares of MediWound in a research note on Wednesday, September 16th. TD Cowen restated a “buy” rating on shares of MediWound in a research note on Thursday, September 24th. Wall Street Zen raised MediWound from a “strong sell” rating to a “sell” rating in a report on Saturday, September 26th. Weiss Ratings lowered MediWound from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, September 8th. Finally, Oppenheimer reiterated an “outperform” rating and set a $30.00 target price (down from $32.00) on shares of MediWound in a research report on Friday, August 14th. Four investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $33.00.

Insider Activity at MediWound

In related news, COO Shmuel Hess sold 3,958 shares of the company’s stock in a transaction that occurred on Thursday, August 27th. The stock was sold at an average price of $12.92, for a total value of $51,137.36. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 9.20% of the company’s stock.

About MediWound

MediWound Ltd. (NASDAQ: MDWD) is a commercial-stage biotechnology company focused on developing and marketing innovative enzymatic therapies for complex wounds. The company’s products are designed to support the removal of damaged tissue and improve wound management, with an emphasis on severe burns and hard-to-heal chronic wounds.

MediWound’s lead product, NexoBrid, is a bromelain-based topical biological product used for the enzymatic removal of eschar, or dead tissue, from deep partial-thickness and full-thickness thermal burns.